Kanada - İngilizce - Health Canada

pharmascience inc - metoclopramide hydrochloride - tablet - 10mg - metoclopramide hydrochloride 10mg - prokinetic agents

ABD - İngilizce - NLM (National Library of Medicine)

a-s medication solutions - metoclopramide hydrochloride (unii: w1792a2rvd) (metoclopramide - unii:l4yeb44i46) - metoclopramide 10 mg - metoclopramide tablets are indicated for the: - treatment for 4 to 12 weeks of symptomatic, documented gastroesophageal reflux in adults who fail to respond to conventional therapy. treatment for 4 to 12 weeks of symptomatic, documented gastroesophageal reflux in adults who fail to respond to conventional therapy. - relief of symptoms in adults with acute and recurrent diabetic gastroparesis. relief of symptoms in adults with acute and recurrent diabetic gastroparesis. limitations of use: metoclopramide  tablets are not recommended for use in pediatric patients due to the risk of developing tardive dyskinesia (td) and other extrapyramidal symptoms as well as the risk of methemoglobinemia in neonates [see use in specific populations (8.4)]. metoclopramide is contraindicated: - in patients with a history of tardive dyskinesia (td) or a dystonic reaction to metoclopramide [see warnings and precautions (5.1, 5.2)]. - when stimulation of gastrointestinal motility might be dangerous (e.g., in the presence of

ABD - İngilizce - NLM (National Library of Medicine)

rebel distributors corp. - metoclopramide hydrochloride (unii: w1792a2rvd) (metoclopramide - unii:l4yeb44i46) - metoclopramide hydrochloride 5 mg - symptomatic gastroesophageal reflux: metoclopramide tablets are indicated as short-term (4 to 12 weeks) therapy for adults with symptomatic, documented gastroesophageal reflux who fail to respond to conventional therapy. the principal effect of metoclopramide is on symptoms of postprandial and daytime heartburn with less observed effect on nocturnal symptoms. if symptoms are confined to particular situations, such as following the evening meal, use of metoclopramide as single doses prior to the provocative situation should be considered, rather than using the drug throughout the day. healing of esophageal ulcers and erosions has been endoscopically demonstrated at the end of a 12-week trial using doses of 15 mg q.i.d. as there is no documented correlation between symptoms and healing of esophageal lesions, patients with documented lesions should be monitored endoscopically. diabetic gastroparesis (diabetic gastric stasis): metoclopramide is indicated for the relief of symptoms associated with acute and recu

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

bridgewest perth pharma pty ltd - metoclopramide hydrochloride, quantity: 10 mg - injection, solution - excipient ingredients: sodium chloride; water for injections; hydrochloric acid; sodium hydroxide - indications as at 23 july 2001: adults (20 years or older) * relief of nausea and vomiting associated with migraine, cancer therapy (chemotherapy or radiation), malignant disease, labour, infectious disease and uraemia * control of post operative vomiting * assist in small bowel intubation. metoclopramide is of little benefit for the prevention or treatment of motion sickness. young adults and children metoclopramide should be restricted to the following conditions when used to treat children and young adults under 20 years of age because of the risk of adverse effects. * severe intractable vomiting of known cause * vomiting associated with radiation therapy or intolerance to cytotoxic drugs * assist in small bowel intubation. young adults and children (over 1 year of age)*metoclopramide should be restricted to the following conditions and only used as second line therapy, when used to treat children and young adults under 20 years of age because of the risk of adverse effects: *severe intractable vomiting o

Belçika - İngilizce - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

sanofi belgium sa-nv - metoclopramide hydrochloride 10 mg/2 ml - solution for injection - 10 mg/ 2 ml - metoclopramide hydrochloride 10 mg - metoclopramide

Yeni Zelanda - İngilizce - Medsafe (Medicines Safety Authority)

ipca pharma (nz) pty limited - metoclopramide hydrochloride 10mg - film coated tablet - 10 mg - active: metoclopramide hydrochloride 10mg excipient: colloidal silicon dioxide hypromellose macrogol 6000 maize starch microcrystalline cellulose pregelatinised maize starch purified talc stearic acid titanium dioxide - adults (20 years and over) digestive disorders metoclopramide restores normal co-ordination and tone to the upper digestive tract and relieves symptoms of gastroduodenal dysfunction including: · dyspepsia · heartburn · flatulence · sickness · regurgitation of bile · pain. these symptoms may be associated with such conditions as: · peptic ulcer · duodenitis · reflux oesophagitis · gastritis · hiatus hernia · cholelithiasis and post-cholecystectomy dyspepsia. nausea and vomiting metoclopramide is indicated in the treatment of nausea and vomiting associated with: · gastrointestinal disorders · cyclical vomiting · intolerance to cytotoxic medicines migraine metoclopramide relieves symptoms of nausea and vomiting, and overcomes gastric stasis associated with attacks of migraine. this improvement in gastric emptying assists the absorption of concurrently administered oral antimigraine therapy (e.g. paracetamol) which may otherwise be impaired in such patients. post-operative conditions · post-operative gastric hypotonia · post-vagotomy syndrome. metoclopramide promotes normal gastric emptying and restores motility in vagotomised patients, and where postoperative symptoms suggest gastroduodenal dysfunction. diagnostic procedures · radiology · duodenal intubation. metoclopramide speeds up the passage of a barium meal by decreasing gastric emptying time, co-ordinating peristalsis and dilating the duodenal bulb. metoclopramide also facilitates duodenal intubation procedures. young adults and children the use of metoclopramide in patients under 20 years should be restricted to the following: · severe intractable vomiting of known cause · vomiting associated with radiotherapy and intolerance to cytotoxic medicines · as an aid to gastrointestinal intubation · as part of the premedication before surgical procedures

Belçika - İngilizce - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

sanofi belgium sa-nv - metoclopramide hydrochloride 10 mg - tablet - 10 mg - metoclopramide hydrochloride 10 mg - metoclopramide

Belçika - İngilizce - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

dechra regulatory b.v. - metoclopramide hydrochloride 10 mg - eq. metoclopramide 8,92 mg - chewable tablet - 10 mg - metoclopramide hydrochloride 10 mg - metoclopramide - dog

Kanada - İngilizce - Health Canada

pro doc limitee - metoclopramide hydrochloride - tablet - 10mg - metoclopramide hydrochloride 10mg - prokinetic agents

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

ipca pharma (australia) pty ltd - metoclopramide hydrochloride, quantity: 5 mg - tablet, film coated - excipient ingredients: maize starch; pregelatinised maize starch; titanium dioxide; microcrystalline cellulose; macrogol 6000; purified talc; hypromellose; stearic acid; colloidal anhydrous silica - in adults (20 years and over): as an adjunct to x-ray examination of the stomach and duodenum. to assist in intestinal intubation. to control nausea and vomiting associated with the following conditions: intolerance to essential drugs possessing emetic properties; uraemia; radiation sickness; malignant disease; postoperative vomiting; labour; infectious diseases. there is no clear benefit in motion sickness or other labyrinth disturbances. metoclopramide hydrochloride has been found useful in the management of gastric retention after gastric surgery. metoclopramide hydrochloride may be useful in the treatment of diabetic gastroparesis of mild to moderate severity. once control of diabetes has been established by diet and/or insulin, metoclopramide hydrochloride should be discontinued.,young adults: the use of metoclopramide hydrochloride in patients under 20 years should be restricted to the following situations: severe intractable vomiting of known cause. vomiting associated with radiotherapy and intolerance to cytotoxic drugs. as an aid to gastrointestinal intubation